Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Laila StaerkT A GerdsG Y H LipB OzenneA N BondeM LambertsE L FosbølC Torp-PedersenG H GislasonJ B OlesenPublished in: Journal of internal medicine (2017)
Standard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.